Chronic Sleep Disruption Alters Gut Microbiota, Induces Systemic and Adipose Tissue Inflammation and Insulin Resistance in Mice

Valeriy Poroyko(City Of Hope National Medical Center), Alba Carreras(University of Chicago), Abdelnaby Khalyfa(University of Chicago), Ahamed Khalyfa(University of Chicago), Vanessa Leone(University of Chicago), Eduard Peris(University of Chicago), Isaac Almendros(University of Chicago), Alex Gileles‐Hillel(University of Chicago), Zhuanhong Qiao(University of Chicago), Nathaniel Hubert(University of Chicago), Ramón Farré(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), Eugene B. Chang(University of Chicago), David Gozal(University of Chicago)
Scientific Reports
October 14, 2016
Cited by 466Open Access
Full Text

Abstract

Chronic sleep fragmentation (SF) commonly occurs in human populations, and although it does not involve circadian shifts or sleep deprivation, it markedly alters feeding behaviors ultimately promoting obesity and insulin resistance. These symptoms are known to be related to the host gut microbiota. Mice were exposed to SF for 4 weeks and then allowed to recover for 2 weeks. Taxonomic profiles of fecal microbiota were obtained prospectively, and conventionalization experiments were performed in germ-free mice. Adipose tissue insulin sensitivity and inflammation, as well as circulating measures of inflammation, were assayed. Effect of fecal water on colonic epithelial permeability was also examined. Chronic SF-induced increased food intake and reversible gut microbiota changes characterized by the preferential growth of highly fermentative members of Lachnospiraceae and Ruminococcaceae and a decrease of Lactobacillaceae families. These lead to systemic and visceral white adipose tissue inflammation in addition to altered insulin sensitivity in mice, most likely via enhanced colonic epithelium barrier disruption. Conventionalization of germ-free mice with SF-derived microbiota confirmed these findings. Thus, SF-induced metabolic alterations may be mediated, in part, by concurrent changes in gut microbiota, thereby opening the way for gut microbiome-targeted therapeutics aimed at reducing the major end-organ morbidities of chronic SF.


Related Papers

No related papers found

Powered by citation graph analysis